<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630108</url>
  </required_header>
  <id_info>
    <org_study_id>B2015-146R</org_study_id>
    <nct_id>NCT02630108</nct_id>
  </id_info>
  <brief_title>TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma</brief_title>
  <official_title>Clinical Study of Transarterial Chemoembolization (TACE) Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Cancer Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian University affiliated Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a prospective and multi-center clinical research in China to compare the efficacy,
      safety and related impact factors between TACE alone and TACE combined with synchronous
      multi-point MWA/RFA for large and huge liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an open random prospective phase III clinical trial conducted by Principal Investigator
      Professor Jian-Hua Wang. Investigators in twenty-five hospitals in China participate in.
      Patients with unresectable large HCC (&gt;5cm in diameter) and huge HCC (&gt;=10cm in diameter) are
      enrolled. The investigators propose to recruitment 280 patients who are randomly assigned
      into the combined group (treated with TACE and synchronous ablation) and the control group
      (treated with TACE alone) according to the proportion of 1:1, which means 140 patients in
      each group. The criteria of inclusion and exclusion, and the methods of lab tests, imaging
      modality and treatment procedures are the same.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of randomization until the date of death from any cause, assessed up to 26 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-Disease Progression</measure>
    <time_frame>From the date of first procedure of TACE or TACE combined with synchronous ablation until the time when the disease progresses from an intermediate to an advanced stage as defined by specific events, assessed up to 26 months</time_frame>
    <description>TTDP follow-up is done at three months interval after lesions defined as stable with treatment of TACE or ablation combined with synchronous TACE six months after enrollment until lesions are defined as disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Six months after the date of first procedure of TACE or TACE combined with synchronous ablation.</time_frame>
    <description>The ratio of CR plus PR. The efficacy is defined as complete regression (CR), partial regression (PR), stable disease (SD) and progressive disease (PD) according to modified Response Evaluation Criteria in Solid Tumors (mRESIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>From the date of first procedure of TACE or TACE combined with synchronous ablationto until the time when lesions are defined as disease progression or death by any cause,assessed up to 26 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of TACE and TACE combined with ablation cycles</measure>
    <time_frame>From the date of randomization until the date of death, assessed up to 26 months.</time_frame>
    <description>The times of the subjects undergoing TACE or TACE combined with ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and severe adverse events in TACE alone and TACE combined with ablation groups</measure>
    <time_frame>From the date of randomization until the date of follow-up visit (30 days after the procedure of TACE or TACE combined with thermal ablation)</time_frame>
    <description>Serious or mild adverse events after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Thermal Ablation &amp; TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.
EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal Ablation</intervention_name>
    <description>Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.</description>
    <arm_group_label>Thermal Ablation &amp; TACE</arm_group_label>
    <other_name>Radiofrequency ablation</other_name>
    <other_name>Microwave ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EADM</intervention_name>
    <description>EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.</description>
    <arm_group_label>Thermal Ablation &amp; TACE</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
    <other_name>Epirubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultra-fluid lipiodol</intervention_name>
    <description>Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .</description>
    <arm_group_label>Thermal Ablation &amp; TACE</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
    <other_name>lipiodol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gelatin sponge articles</intervention_name>
    <description>Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.</description>
    <arm_group_label>Thermal Ablation &amp; TACE</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with primary liver cancer aged from 18-80 years, and life expectancy longer
             than three months;

          2. Patients with large HCC (&gt;5cm in diameter) and huge HCC (≥10cm in diameter), including
             HCC and mixed type of liver cancer (HCC-ICC);

          3. Patients with no thrombus in main portal vein (PV)

          4. Patients' liver function classified as Child-Pugh A or B, ECOG PS ≤ 2;

          5. Patients without bleeding tendency or coagulation disorder, or with reversible
             coagulopathy after therapy;

          6. White blood cell count ≥ 3.0×10^9/L;

          7. Hemoglobin ≥ 8.5g/dl;

          8. Platelet ≥ 50×10^9/L;

          9. INR ≤ 2.3 or PT not exceeding the upper limit of reference 3 seconds;

         10. Blood creatinine less than 1.5 times of upper limit of reference;

         11. Patients and/or their relatives willing to join in the clinical trial and signing the
             informed consent.

        Exclusion Criteria:

          1. Patients with diffuse type of liver cancer;

          2. Cholangiocellular carcinoma

          3. Patients with main PV thrombus;

          4. Patients with hepatic vein thrombus;

          5. Patients with lymph node or distant metastasis outside of liver;

          6. Patients' liver function classified as Child-Pugh C and no improvement after treatment
             of liver protection;

          7. Patients with irreversible coagulation disorder and abnormality in blood routine test,
             or having obvious bleeding tendency;

          8. Patients with intractable massive ascites;

          9. Patients' ECOG PS &gt;2;

         10. Patients complicated with active infection, especially cholangitis;

         11. Patients with severe disorders of heart, lungs, kidneys, or brain;

         12. Patients and/or their relatives refuse to anticipate this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhua Wang, MD</last_name>
    <phone>+8613611759557</phone>
    <email>wang.jianhua@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Liu, MD</last_name>
    <phone>+8613681971563</phone>
    <email>liu.rong@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Wang, MD</last_name>
      <phone>+8613611749557</phone>
      <email>wang.jianhua@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Rong Liu, MD</last_name>
      <phone>+8613681971563</phone>
      <email>liu.rong@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jianhua Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.3322/caac.21254/epdf</url>
    <description>Link Text: wiley</description>
  </link>
  <link>
    <url>http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(11)61347-0.pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://www.biomedcentral.com/content/pdf/1471-230X-14-11.pdf</url>
    <description>Link Text:BioMed Central</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2354.2008.00984.x/pdf</url>
    <description>Link Text:Wiley</description>
  </link>
  <link>
    <url>http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(02)08649-X.pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://www.redjournal.org/article/S0360-3016(09)02919-8/pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://www.americanjournalofsurgery.com/article/S0002-9610(08)00047-0/pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://www.tandfonline.com/doi/pdf/10.3109/02656736.2011.605099</url>
    <description>Link Text:Taylor &amp; Francis</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582496/pdf/ci089001.pdf</url>
    <description>Link Text:PubMed Central</description>
  </link>
  <link>
    <url>http://pubs.rsna.org/doi/pdf/10.1148/radiology.210.3.r99fe40655</url>
    <description>Link Text:Atypon - PDF</description>
  </link>
  <link>
    <url>http://pubs.rsna.org/doi/pdf/10.1148/radiol.2282021787</url>
    <description>Link Text:Atypon - PDF</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665233/pdf/ci050103.pdf</url>
    <description>Link Text:PubMed Central</description>
  </link>
  <link>
    <url>http://search.proquest.com/docview/213492101?accountid=10025</url>
    <description>Link Text:ProQuest Health and Medical Complete New Platform</description>
  </link>
  <link>
    <url>http://www.tandfonline.com/doi/pdf/10.1080/0265673021000017154</url>
    <description>Link Text:Taylor &amp; Francis</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/jgh.12088/epdf</url>
    <description>Link Text:Wiley</description>
  </link>
  <link>
    <url>http://pubs.acs.org/doi/ipdf/10.1021/acs.est.5b01953</url>
    <description>Link Text:American Chemical Society</description>
  </link>
  <link>
    <url>https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0030-1247132</url>
    <description>Link Text:Georg Thieme Verlag Stuttgart, New York</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0168827811008658/pdfft?md5=382e0760eebb3e25fb3ae8e6caf2dd74&amp;pid=1-s2.0-S0168827811008658-main.pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://www.biomedcentral.com/content/pdf/1471-2407-14-601.pdf</url>
    <description>Link Text:BioMed Central</description>
  </link>
  <link>
    <url>http://pubs.rsna.org/doi/10.1148/radiol.11110144?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</url>
    <description>Link Text:Link Text:</description>
  </link>
  <link>
    <url>http://www.jvir.org/article/S1051-0443(09)00308-X/pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://search.proquest.com/docview/1032640168?accountid=10025</url>
    <description>Link Text:ProQuest Health and Medical Complete New Platform</description>
  </link>
  <link>
    <url>http://link.springer.com/content/pdf/10.1007%2Fs00464-014-3617-4.pdf</url>
    <description>Link Text:Springer</description>
  </link>
  <link>
    <url>http://ar.iiarjournals.org/content/33/3/1221.full.pdf+html</url>
    <description>Link Text:HighWire</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0009926012002188/pdfft?md5=efd8576c9163392cff4e81f35d4ba888&amp;pid=1-s2.0-S0009926012002188-main.pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/cncr.24196/pdf</url>
    <description>Link Text:Wiley</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2007.00190.x/full</url>
    <description>Link Text:Wiley</description>
  </link>
  <link>
    <url>http://pubs.rsna.org/doi/pdf/10.1148/radiol.2513081740</url>
    <description>Link Text:Atypon - PDF</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0009926013000263/pdfft?md5=a4bd8541fd409f4459f4b2e68348d468&amp;pid=1-s2.0-S0009926013000263-main.pdf</url>
    <description>Link Text:Elsevier Science</description>
  </link>
  <results_reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.</citation>
    <PMID>25559415</PMID>
  </results_reference>
  <results_reference>
    <citation>Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012 Mar 31;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. Epub 2012 Feb 20. Review.</citation>
    <PMID>22353262</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang L, Yin X, Gan YH, Zhang BH, Zhang JB, Chen Y, Xie XY, Ge NL, Wang YH, Ye SL, Ren ZG. Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. BMC Gastroenterol. 2014 Jan 10;14:11. doi: 10.1186/1471-230X-14-11.</citation>
    <PMID>24410841</PMID>
  </results_reference>
  <results_reference>
    <citation>Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9. doi: 10.1111/j.1365-2354.2008.00984.x.</citation>
    <PMID>19453695</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.</citation>
    <PMID>12049862</PMID>
  </results_reference>
  <results_reference>
    <citation>Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, Suh DJ. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):180-7. doi: 10.1016/j.ijrobp.2009.07.1730. Epub 2009 Nov 18.</citation>
    <PMID>19926229</PMID>
  </results_reference>
  <results_reference>
    <citation>Shiomi H, Naka S, Sato K, Demura K, Murakami K, Shimizu T, Morikawa S, Kurumi Y, Tani T. Thoracoscopy-assisted magnetic resonance guided microwave coagulation therapy for hepatic tumors. Am J Surg. 2008 Jun;195(6):854-60. doi: 10.1016/j.amjsurg.2007.08.056. Epub 2008 Mar 26.</citation>
    <PMID>18355796</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, Liu C. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int J Hyperthermia. 2011;27(7):654-62. doi: 10.3109/02656736.2011.605099. Epub 2011 Oct 3.</citation>
    <PMID>21966941</PMID>
  </results_reference>
  <results_reference>
    <citation>Gillams A. Tumour ablation: current role in the liver, kidney, lung and bone. Cancer Imaging. 2008 Oct 4;8 Spec No A:S1-5. doi: 10.1102/1470-7330.2008.9001. Review.</citation>
    <PMID>18852074</PMID>
  </results_reference>
  <results_reference>
    <citation>Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999 Mar;210(3):655-61.</citation>
    <PMID>10207464</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldberg SN, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan JP, Rhim H, Silverman SG, Solbiati L, Vogl TJ, Wood BJ; International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology. 2003 Aug;228(2):335-45.</citation>
    <PMID>12893895</PMID>
  </results_reference>
  <results_reference>
    <citation>Gillams AR. Image guided tumour ablation. Cancer Imaging. 2005 Sep 21;5:103-9. Review.</citation>
    <PMID>16305946</PMID>
  </results_reference>
  <results_reference>
    <citation>Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother. 2003 Feb;52(2):80-8. Epub 2003 Jan 29.</citation>
    <PMID>12594571</PMID>
  </results_reference>
  <results_reference>
    <citation>Dong BW, Zhang J, Liang P, Yu XL, Su L, Yu DJ, Ji XL, Yu G. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia. 2003 Mar-Apr;19(2):119-33.</citation>
    <PMID>12623635</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, Zhou JX, Hu RM, Tan QY. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013 Mar;28(3):456-63. doi: 10.1111/jgh.12088.</citation>
    <PMID>23216261</PMID>
  </results_reference>
  <results_reference>
    <citation>Cross FA, Evans DW, Barber RT. Decadal Declines of Mercury in Adult Bluefish (1972-2011) from the Mid-Atlantic Coast of the U.S.A. Environ Sci Technol. 2015 Aug 4;49(15):9064-72. doi: 10.1021/acs.est.5b01953. Epub 2015 Jul 21.</citation>
    <PMID>26148053</PMID>
  </results_reference>
  <results_reference>
    <citation>Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Review.</citation>
    <PMID>20175033</PMID>
  </results_reference>
  <results_reference>
    <citation>Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012 Apr;56(4):886-92. doi: 10.1016/j.jhep.2011.10.021. Epub 2011 Dec 13.</citation>
    <PMID>22173160</PMID>
  </results_reference>
  <results_reference>
    <citation>Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, Golfieri R; BLOG-Bologna Liver Oncology Group, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer. 2014 Aug 19;14:601. doi: 10.1186/1471-2407-14-601.</citation>
    <PMID>25139639</PMID>
  </results_reference>
  <results_reference>
    <citation>Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012 Jan;262(1):43-58. doi: 10.1148/radiol.11110144. Review.</citation>
    <PMID>22190656</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG, Solbiati L, Vogl TJ, Wood BJ, Vedantham S, Sacks D; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S377-90. doi: 10.1016/j.jvir.2009.04.011.</citation>
    <PMID>19560026</PMID>
  </results_reference>
  <results_reference>
    <citation>Qian GJ, Wang N, Shen Q, Sheng YH, Zhao JQ, Kuang M, Liu GJ, Wu MC. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol. 2012 Sep;22(9):1983-90. doi: 10.1007/s00330-012-2442-1. Epub 2012 Apr 28.</citation>
    <PMID>22544225</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc. 2014 Dec;28(12):3429-34. doi: 10.1007/s00464-014-3617-4. Epub 2014 Jun 17.</citation>
    <PMID>24935203</PMID>
  </results_reference>
  <results_reference>
    <citation>Poggi G, Montagna B, DI Cesare P, Riva G, Bernardo G, Mazzucco M, Riccardi A. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer Res. 2013 Mar;33(3):1221-7.</citation>
    <PMID>23482806</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, Zheng Y, Li S, Li B, Zhang Y, Yuan Y. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin Radiol. 2013 Jan;68(1):21-6. doi: 10.1016/j.crad.2012.05.007. Epub 2012 Jul 4.</citation>
    <PMID>22766484</PMID>
  </results_reference>
  <results_reference>
    <citation>Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol. 2014 Dec 14;20(46):17483-90. doi: 10.3748/wjg.v20.i46.17483.</citation>
    <PMID>25516662</PMID>
  </results_reference>
  <results_reference>
    <citation>Yin XY, Xie XY, Lu MD, Xu HX, Xu ZF, Kuang M, Liu GJ, Liang JY, Lau WY. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009 May 1;115(9):1914-23. doi: 10.1002/cncr.24196.</citation>
    <PMID>19241423</PMID>
  </results_reference>
  <results_reference>
    <citation>Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatol Res. 2007 Sep;37 Suppl 2:S230-7.</citation>
    <PMID>17877488</PMID>
  </results_reference>
  <results_reference>
    <citation>Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology. 2009 Jun;251(3):933-40. doi: 10.1148/radiol.2513081740. Epub 2009 Mar 20.</citation>
    <PMID>19304921</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, Du Z. Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques. Clin Radiol. 2013 Jun;68(6):608-15. doi: 10.1016/j.crad.2012.12.008. Epub 2013 Feb 8.</citation>
    <PMID>23399463</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>TACE</keyword>
  <keyword>Thermal Ablation</keyword>
  <keyword>Safety/Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

